지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2015.1
- 수록면
- 343 - 361 (19page)
이용수
초록· 키워드
오류제보하기
Evidence suggests that combined gemcitabine-cisplatin chemotherapy extends survival in patients with advanced biliary tract cancer (BTC). We conducted a systematic review in order to collate this evidence and assess whether gemcitabine-cisplatin efficacy is influenced by primary tumor site, disease stage, or geographic region, and whether associated toxicities are related to regimen. MEDLINE (1946-search date), EMBASE (1966-search date), ClinicalTrials.
gov (2008-search date), and abstracts from major oncology conferences (2009- search date) were searched (5 Dec 2013) using terms for BTC, gemcitabine, and cisplatin.
All study types reporting efficacy (survival, response rates) or safety (toxicities) outcomes of gemcitabine-cisplatin in BTC were eligible for inclusion; efficacy data were extracted from prospective studies only. Evidence retrieved from one meta-analysis (abstract), four randomized controlled trials, 12 nonrandomized prospective studies, and three retrospective studies supported the efficacy and safety of gemcitabine-cisplatin for BTC. Median overall survival ranged from 4.6 to 11.7 months, and response rate ranged from 17.1% to 36.6%.
Toxicities were generally acceptable and manageable. Heterogeneity in study designs and data collected prevented formal meta-analysis, however exploratory assessments suggested that efficacy did not vary with primary tumor site (gallbladder vs. others), disease stage (metastatic vs. locally advanced), or geographic origin (Asia vs. other). Incidence of grade 3/4 toxicities was not related to gemcitabine dose or cisplatin frequency. Despite individual variation in study designs, the evidence presented suggests that gemcitabine-cisplatin is effective in patients from a diverse range of countries and with heterogeneous disease characteristics.
No substantial differences in toxicity were observed among the different dosing schedules of gemcitabine and cisplatin.
목차
등록된 정보가 없습니다.
참고문헌 (24)
참고문헌 신청
[학
/ 2013 / Gemzar (gemcitabine for injection) [prescribing information] / Eli Lilly and Company;
Charoentum C / 2007 / Experience with gemcitabine and cisplatin in the therapy of inoperable and metastatic cholangiocarcinoma / World J Gastroenterol 13 : 2852 ~ 2854
Doval DC / 2004 / A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer / Br J Cancer 90 : 1516 ~ 1520
Eckel F / 2007 / Chemotherapy in advanced biliary tract carcinoma : a pooled analysis of clinical trials / Br J Cancer 96 : 896 ~ 902
/ 2013 / Gemzar (gemcitabine for injection) [prescribing information] / Eli Lilly and Company;
Charoentum C / 2007 / Experience with gemcitabine and cisplatin in the therapy of inoperable and metastatic cholangiocarcinoma / World J Gastroenterol 13 : 2852 ~ 2854
Doval DC / 2004 / A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer / Br J Cancer 90 : 1516 ~ 1520
Eckel F / 2007 / Chemotherapy in advanced biliary tract carcinoma : a pooled analysis of clinical trials / Br J Cancer 96 : 896 ~ 902
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer
Cancer Research and Treatment
2021 .10
-
An Updated Meta-analysis and System Review:is Gemcitabine+Fluoropyrimidine in Combination a Better Therapy Versus Gemcitabine Alone for Advanced and Unresectable Pancreatic Cancer?
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
A Single-Arm Phase II Study of Nab-Paclitaxel Plus Gemcitabine and Cisplatin for Locally Advanced or Metastatic Biliary Tract Cancer
Cancer Research and Treatment
2024 .04
-
Comparison of the Efficacy between Gemcitabine-Cisplatin and Capecitabine-Cisplatin Combination Chemotherapy for Advanced Biliary Tract Cancer
Cancer Research and Treatment
2015 .01
-
Induction Chemotherapy with Gemcitabine and Cisplatin Followed by Simultaneous Integrated Boost–Intensity Modulated Radiotherapy with Concurrent Gemcitabine for Locally Advanced Unresectable Pancreatic Cancer: Results from a Feasibility Study
Cancer Research and Treatment
2017 .01
-
Systemic Chemotherapy in Advanced Pancreatic Cancer
Gut and Liver
2016 .01
-
Intravesical gemcitabine for non-muscle invasive bladder cancer: An abridged Cochrane Review
Investigative and Clinical Urology
2021 .11
-
Comparison of Single Agent Gemcitabine and Docetaxel in Second-Line Therapy for Advanced Stage Non-Small Cell Lung Cancer in a University Hospital in Turkey
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Surgical resection after gemcitabine, cisplatin, and nab-paclitaxel chemotherapy for locally advanced cholangiocarcinoma: A retrospective single-center study
Annals of Hepato-Biliary-Pancreatic Surgery
2021 .12
-
Clinical Feasibility of Curative Surgery after nab-Paclitaxel Plus Gemcitabine-cisplatin Chemotherapy in Patients with Locally Advanced Cholangiocarcinoma
대한외과학회 학술대회 초록집
2022 .11
-
Effect of surfactant on the preparation and characterization of gemcitabine-loaded particles
Journal of Pharmaceutical Investigation
2019 .01
-
[Surgical Oncology] Short-term Outcomes of Radical Surgery after nab-Paclitaxel Plus Gemcitabine-cisplatin Chemotherapy in Patients with Locally Advanced Perihilar Cholangiocarcinoma
대한외과학회 학술대회 초록집
2022 .11
-
Comparative analysis of recurrence rates between intravesical gemcitabine and bacillus Calmette–Guérin induction therapy following transurethral resection of bladder tumors in patients with intermediate- and high-risk bladder cancer: A retrospective multicenter study
Investigative and Clinical Urology
2024 .05
-
A Pooled Study on Combination of Gemcitabine and Nedaplatin for Treating Patients with Non-small Cell Lung Cancer
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Integrative Meta-Analysis of Multiple Gene Expression Profiles in Acquired Gemcitabine-Resistant Cancer Cell Lines to Identify Novel Therapeutic Biomarkers
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Surgical Resection after Gemcitabine, Cisplatin, and Nab-Paclitaxel Chemotherapy for Locally Advanced Cholangiocarcinoma: A Retrospective Single-Center Study
대한외과학회 학술대회 초록집
2021 .05
-
Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX
Gut and Liver
2021 .01
-
In vitro Study of the Antagonistic Effect of Low-dose Liquiritigenin on Gemcitabine-induced Capillary Leak Syndrome in Pancreatic Adenocarcinoma via Inhibiting ROS-Mediated Signalling Pathways
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Association of GSTP1 and RRM1 Polymorphisms with the Response and Toxicity of Gemcitabine-cisplatin Combination Chemotherapy in Chinese Patients with Non-small Cell Lung Cancer
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer
Cancer Research and Treatment
2015 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0